Stromal/epithelial interactions of murine prostatic cell lines in vivo: A model for benign prostatic hyperplasia and the effect of doxazosin on tissue size

Prostate

Volumn 54, Issue 1, 2003, Pages 17-24

  Takao, Tetsuya ^a,b   Tsujimura, Akira ^a,b   Coetzee, Sandra ^a   Salm, Sarah N ^a   Lepor, Herbert ^a   Shapiro, Ellen ^a   Moscatelli, David ^a   Wilson, E Lynette ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgens; Benign prostatic hyperplasia; Doxazosin; Prostatic cell lines

Indexed keywords

ANDROGEN; DOXAZOSIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASAL CELL; CASTRATION; CELL INTERACTION; CELL LINE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; HORMONE RESPONSE; IN VIVO STUDY; INOCULATION; KIDNEY CAPSULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SECRETION; SMOOTH MUSCLE FIBER; TISSUE GROWTH;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CELL COMMUNICATION; CELL LINE; DISEASE MODELS, ANIMAL; DOXAZOSIN; EPITHELIAL CELLS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MUSCLE, SMOOTH; PROSTATIC HYPERPLASIA; STROMAL CELLS;

EID: 0037220702     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10147     Document Type: Article

References (41)

1. Walsh PC. Human benign prostatic hyperplasia: Etiological considerations. Prog Clin Biol Res 1984;145:1-25.
2. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
3. Bartsch G, Muller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122:487-491.
4. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293-1297.
5. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, Cunha GR. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 1998;63:131-140.
6. Cunha GR, Chung LW. Stromal-epithelial interactions. I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 1981;14:1317-1324.
7. Sugimura Y, Cunha GR, Bigsby RM. Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized (Tfm/Y) mice. Prostate 1986;9:217-225.
8. Norman JT, Cunha GR, Sugimura Y. The induction of new ductal growth in adult prostatic epithelium in response to an embryonic prostatic inductor. Prostate 1986;8:209-220.
9. Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997;31:131-138.
10. Colombel M, Vacherot F, Diez SG, Fontaine E, Buttyan R, Chopin D. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. Br J Urol 1998;82:380-385.
11. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340-345.
12. McNeal JE. The prostate gland: Morphology and pathobiology. In: Stamey TA, editor. Monographs in Urology. Princeton, NJ: Burroughs Welcome Co.; 1988. p 36-54.
13. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998;160:2381-2392.
14. Berry SJ, Isaacs JT. Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology 1984;114:511-520.
15. DeKlerk DP, Coffey DS, Ewing LL, McDermott IR, Reiner WG, Robinson CH, Scott WW, Strandberg JD, Talalay P, Walsh PC, Wheaton LG, Zirkin BR. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1979;64:842-849.
16. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21:58-64.
17. Tutrone RF Jr, Ball RA, Ornitz DM, Leder P, Richie JP. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model. J Urol 1993;149:633-639.
18. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest 1996;74:747-760.
19. Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions. I. Induction of neuronal phenotypes. Prostate 1997;33:151-156.
20. Salm SN, Koikawa Y, Ogilvie V, Tsujimura A, Coetzee S, Moscatelli D, Moore E, Lepor H, Shapiro E, Sun TT, Wilson EL. Generation of active TGF-beta by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. J Cell Physiol 2000;184:70-79.
21. Salm SN, Koikawa Y, Ogilvie V, Tsujimura A, Coetzee S, Moscatelli D, Moore E, Lepor H, Shapiro E, Sun TT, Wilson EL. Transforming growth factor-beta is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1. J Cell Physiol 2000;185:416-424.
22. Salm SN, Takao T, Tsujimura A, Coetzee S, Moscatelli D, Wilson EL. Differentiation and stromal-induced growth promotion of murine prostatic tumors. Prostate 2002;51:175-188.
23. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions. II. Induction of apoptosis by doxazosin. Prostate 1997;33:157-163.
24. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-4555.
25. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR. The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 1999;39:205-212.
26. Alabaster VA, Davey MJ. The alpha 1-adrenoceptor antagonist profile of doxazosin: Preclinical pharmacology. Br J Clin Pharmacol 1986;21:9S-17S.
27. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 1986;21:19S-25S.
28. Fingert HJ, Chen Z, Mizrahi N, Gajewski WH, Bamberg MP, Kradin RL. Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay. Cancer Res 1987;47:3824-3829.
29. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994;74:1030-1044.
30. Cunha GR, Hayward SW, Dahiya R, Foster BA. Smooth muscleepithelial interactions in normal and neoplastic prostatic development. Acta Anat 1996;155:63-72.
31. Kinbara H, Cunha GR, Boutin E, Hayashi N, Kawamura J. Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate 1996;29:107-116.
32. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 1994;134:1039-1045.
33. Farnsworth WE. Prostate stroma: Physiology. Prostate 1999;38:60-72.
34. Bretland AJ, Reid SV, Chapple CR, Eaton CL. Role of endogenous transforming growth factor beta (TGFbeta)1 in prostatic stromal cells. Prostate 2001;48:297-304.
35. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 1997;232:208-215.
36. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: Abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol 2000;164:215-223.
37. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999;39:285-290.
38. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597-641.
39. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: Structural features and mechanisms of activation. Kidney Int 1997;51:1376-1382.
40. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001;46:45-51.
41. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999;161:2002-2008.